PortfoliosLab logo
RARE vs. SANA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between RARE and SANA is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

RARE vs. SANA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ultragenyx Pharmaceutical Inc. (RARE) and Sana Biotechnology, Inc. (SANA). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

RARE:

-0.34

SANA:

-0.41

Sortino Ratio

RARE:

-0.29

SANA:

-0.77

Omega Ratio

RARE:

0.97

SANA:

0.91

Calmar Ratio

RARE:

-0.20

SANA:

-0.84

Martin Ratio

RARE:

-0.74

SANA:

-1.33

Ulcer Index

RARE:

22.09%

SANA:

61.55%

Daily Std Dev

RARE:

43.27%

SANA:

187.98%

Max Drawdown

RARE:

-82.49%

SANA:

-96.92%

Current Drawdown

RARE:

-80.21%

SANA:

-95.82%

Fundamentals

Market Cap

RARE:

$3.65B

SANA:

$426.15M

EPS

RARE:

-$6.29

SANA:

-$1.16

PS Ratio

RARE:

6.59

SANA:

0.00

PB Ratio

RARE:

14.45

SANA:

1.70

Total Revenue (TTM)

RARE:

$451.40M

SANA:

$0.00

Gross Profit (TTM)

RARE:

$383.34M

SANA:

-$3.90M

EBITDA (TTM)

RARE:

-$323.47M

SANA:

-$149.04M

Returns By Period

In the year-to-date period, RARE achieves a -16.54% return, which is significantly lower than SANA's 11.66% return.


RARE

YTD

-16.54%

1M

3.54%

6M

-30.28%

1Y

-14.82%

5Y*

-11.30%

10Y*

-6.98%

SANA

YTD

11.66%

1M

17.42%

6M

-39.43%

1Y

-75.73%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

RARE vs. SANA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RARE
The Risk-Adjusted Performance Rank of RARE is 3333
Overall Rank
The Sharpe Ratio Rank of RARE is 3232
Sharpe Ratio Rank
The Sortino Ratio Rank of RARE is 2929
Sortino Ratio Rank
The Omega Ratio Rank of RARE is 2929
Omega Ratio Rank
The Calmar Ratio Rank of RARE is 3939
Calmar Ratio Rank
The Martin Ratio Rank of RARE is 3636
Martin Ratio Rank

SANA
The Risk-Adjusted Performance Rank of SANA is 1717
Overall Rank
The Sharpe Ratio Rank of SANA is 2929
Sharpe Ratio Rank
The Sortino Ratio Rank of SANA is 1717
Sortino Ratio Rank
The Omega Ratio Rank of SANA is 2020
Omega Ratio Rank
The Calmar Ratio Rank of SANA is 44
Calmar Ratio Rank
The Martin Ratio Rank of SANA is 1313
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

RARE vs. SANA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Ultragenyx Pharmaceutical Inc. (RARE) and Sana Biotechnology, Inc. (SANA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current RARE Sharpe Ratio is -0.34, which is comparable to the SANA Sharpe Ratio of -0.41. The chart below compares the historical Sharpe Ratios of RARE and SANA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Dividends

RARE vs. SANA - Dividend Comparison

Neither RARE nor SANA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

RARE vs. SANA - Drawdown Comparison

The maximum RARE drawdown since its inception was -82.49%, smaller than the maximum SANA drawdown of -96.92%. Use the drawdown chart below to compare losses from any high point for RARE and SANA. For additional features, visit the drawdowns tool.


Loading data...

Volatility

RARE vs. SANA - Volatility Comparison


Loading data...

Financials

RARE vs. SANA - Financials Comparison

This section allows you to compare key financial metrics between Ultragenyx Pharmaceutical Inc. and Sana Biotechnology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00MAprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
164.88M
0
(RARE) Total Revenue
(SANA) Total Revenue
Values in USD except per share items